Beijing Zhenzhi Medical Technology
Immune cell therapy drugs for solid tumor treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Seed | |
| Total Funding | 000k | ||
Beijing Zhenzhi Medical Technology Co., Ltd., operating as Immupeutics, is a clinical-stage biotechnology company founded in 2018. The company specializes in developing immune cell therapy drugs, with a specific focus on treating tumors. Its core technology revolves around T-cell receptor (TCR)-T cell therapy, a method that genetically engineers a patient's T cells to recognize and attack cancer cells. This approach allows for the targeting of a wide range of cancer-specific proteins, including those inside the tumor cells, which is a key differentiator from some other cell therapies like CAR-T.
Immupeutics is advancing a pipeline of products, including IPM-514, IPM-001, and IPM103, and is engaged in multiple clinical trials. The firm's business model integrates the research and development of these innovative therapies with companion diagnostic technologies and immunological multi-omics technology to provide integrated treatment solutions for patients. Headquartered in Beijing, China, the company has successfully raised capital to advance its clinical programs. As of September 2023, Immupeutics had raised $15.5 million from investors including Shanghai Junshi Biosciences, Shun Xi Fund, AbogenBio, Alwin Capital, and Lotus Lake Ventures.
Keywords: TCR-T cell therapy, solid tumors, cell therapy, cancer immunotherapy, clinical-stage biotechnology, companion diagnostics, oncology, immune cell therapy, neoplasms, therapeutic vaccine, IPM-514, IPM-001, IPM103, China biotech, multi-omics technology